Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GRANISETRON HCL

All products: not a benefit

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit
  • Nabilone (Cesamet): general benefit, Not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453

Kytril · DIN 02185881 · 1mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-11-06 — choose a marketed DIN from the same-category list.Discontinued 2015-11-06 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2015-11-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2015-11-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 91, 92, 93, 326, 454
Reason for Use code 91 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 92 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 93 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 326 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Kytril · DIN 02185881 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2015-11-06 · brand KYTRIL TABLETS 1MG · ATC A04AA02 GRANISETRON · form Tablet · route Oral · ingredients GRANISETRON (GRANISETRON HYDROCHLORIDE) 1 MG · company Hoffmann-la roche limited · schedule Prescription
Check this DIN again · Health Canada product record

Kytril: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19688 · Verify on the e-Formulary ↗ (DIN 02185881)

Source record
DIN 02185881: Kytril Raw flags: notABenefit=Y, sec3=Y Item: 562200024; group id 666; item number 1654; lccId 00101; manufacturer id HLR Source form: Tab; strength: 1mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02185881 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19688
Interchangeable products
Apo-Granisetron · DIN 02308894 · $4.5000 Jamp Granisetron · DIN 02472686 · $4.5000 Nat-Granisetron · DIN 02452359 · $4.5000
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02185881
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2015-11-06 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: download failed: TimeoutError

Other review policies

For Kytril: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026